| Project/Area Number |
22K15924
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
ドバデル ビム 長崎大学, 熱帯医学研究所, 准教授 (80761113)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2024: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2022: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | Multiplex immunoassay / Pneumococcal vaccines / Antibody titer / children / vaccine immunogenicity / 肺炎球菌ワクチン / マルチプレックス免疫アッセイ / ワクチン血清型 / 抗体価 / Luminex |
|---|
| Outline of Research at the Start |
肺炎球菌ワクチンの効果を調査するために、酵素結合免疫吸着法(ELISA)を用いた抗体測定が行われるが、この方法は非効率的で多くの血清検体を必要とし、費用も高額である。本研究ではこれらの点においていずれも優れているLuminexを用いた、24種のワクチン血清型に対する抗体価を一度で測定可能なアッセイ系を開発し、その有用性を検証する。
次にこのアッセイを用いて、ワクチンを接種した小児や高齢者の唾液を検体とした抗体測定の可能性を明らかにする。次世代肺炎球菌ワクチンの開発が盛んになる中で求められる、小児や高齢者におけるワクチン効果を効率的に評価するための有望なツールの開発を目指す。
|
| Outline of Annual Research Achievements |
We have completed the validation of the microsphere-based assay for all 24 pneumococcal vaccine serotypes. WHO standard ELISA has been established following the protocol developed by the WHO.
We have got the ethical approval from the Institutional Review Board (IRB) of School of Tropical Medicine and Global Health. We have applied for ethical approval from Nepal Health Research Council. Our application has already reviewed and we have addressed the comments raised by the reviewers. Material transfer agreement between the Institute of Tropical Medicine and the Siddhi Memorial Hospital has been completed.
For data and sample collection from the research site, RedCap training is completed and other lab equipment, including a deep freezer of -80 degree centrigrate is established.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
The project is progressing smoothly although it has taken time to complete the laboratory part of assay development and validation along with establishment of WHO ELISA for quantitative assessment of antibodies against pneumococcal vaccine serotypes.
|
| Strategy for Future Research Activity |
We expect to get ethical approval from Nepal Health Research Council by the end of this month. From next month, we plan to enroll children in this project along with collection of blood and saliva. We expected to finished data and sample collection of 300 children within 3 months of start of the project.
We will bring these serum and saliva samples to Institute of Tropical Medicine by the end of August and start testing them with the 24-plex assay. We plan to get the results by October, and start preparing the report.
|
